Aging & Geriatrics
Resources
Basic InformationLatest News
U.S. Air Pollution Still at Deadly Levels, Study Finds75 or Older? Statins Can Still Benefit Your HeartMuscle Relaxants for Back Pain Are Soaring: Are They Safe?Middle-Age Obesity Linked to Higher Odds for DementiaAmid Pandemic, Fears That Older Americans Are Feeling 'Expendable'What Behaviors Will Shorten Your Life?5 Healthy Steps to Lower Your Odds for Alzheimer'sWant Added Years? Try VolunteeringExercise Habits Key to Gauging Seniors' LongevityGet Moving, Seniors: It's Good For Your BrainMillions of Older Americans Can't Get Enough FoodCan Fruits, Tea Help Fend Off Alzheimer's Disease?Vigorous Exercise Safe for Those at Risk of Knee ArthritisMiddle Age More Stressful Now Than in 1990s: StudyPandemic Delaying Medical Care of Older AmericansPneumonia More Deadly Than Hip Fractures for Hospitalized SeniorsActive Older Vets More Likely to Fall, But Less Likely to Get Hurt: StudyEarly On, Many Seniors Were Unfazed by Coronavirus Warnings, Study FindsEven Light Exercise Can Speed Stroke RecoverySheltering at Home? Take Steps to Prevent Injuries From FallsAre Steroids Really the Answer for Arthritic Knees?Heavy Drinking Into Old Age Ups Health Risks: StudyHow Pets Can Be True Lifesavers for SeniorsVitamin D Might Aid Seniors' Recovery From Hip Fracture: StudyMindfulness a Powerful Tool for AgingPandemic Adds to Challenge of Caring for Loved One With DementiaIs Thyroid Hormone Dangerously Overprescribed in Older Patients?Don't Fall Prey to COVID-19 ScammersAHA News: Dropping Blood Pressure May Predict Frailty, Falls in Older PeopleWhen Is Surgery Not Safe for Seniors?Rising Number of Older Americans at Risk of Vision LossU.S. Primary Care Docs Unprepared for Surge in Alzheimer's CasesEven a Little Activity Keeps Aging Brains From Shrinking, Study ShowsSeniors, Getting Off the Sofa Brings Big Health BenefitsHelping Seniors Manage Meds After Hospital Reduces Readmission: StudyMany Seniors Leave Hospital With New DisabilitiesSleepy Seniors Have Higher Health RisksLosing a Spouse Could Speed Brain's DeclineTime Spent on the Links May Lengthen LifeWith Macular Degeneration, 1 Missed Visit to Eye Doc Can Mean Vision LossAgeism Affects People Around the GlobeLife Expectancy in U.S. Increases for First Time in 4 YearsDiets Rich in Fruits, Veggies Could Lower Your Odds for Alzheimer'sBlood Pressure Dips Upon Standing Might Not Be as Dangerous as ThoughtAll in the Timing: Many Get Knee Replacement Too Late or Too SoonWant a Long, Healthy Old Age? A Healthy Middle Age HelpsEven 1 Night's Bad Sleep Can Raise Levels of a Brain 'Marker' for Alzheimer'sSeniors Still Wary of Online Reviews When Picking DoctorsWant to Turn Back the Aging Clock? Train for a MarathonExercise May Keep Your Brain Healthy
Questions and AnswersVideosLinksBook ReviewsSelf-Help Groups
Related Topics

Depression: Depression & Related Conditions
Elder Care

Fish Oil Rx Slows Clogging in Arteries

HealthDay News
by By Dennis Thompson
HealthDay Reporter
Updated: Nov 18th 2019

new article illustration

MONDAY, Nov. 18, 2019 (HealthDay News) -- Prescription-strength fish oil slows the development of artery-clogging plaques, according to early results from an ongoing clinical trial.

Icosapent ethyl, sold under the brand name Vascepa, is a drug derived from fish that contains pure EPA, a key nutrient in fish oil. In the new study, Vascepa appeared to put the brakes on key aspects of plaque formation in vessels after nine months of use, said lead researcher Dr. Matthew Budoff, a professor at UCLA's David Geffen School of Medicine.

"We found significant slowing of progression among four different plaque markers, including total plaque," Budoff noted in a presentation on Monday at the American Heart Association's annual meeting, in Philadelphia.

These early results provide some tantalizing hints why icosapent ethyl was found to reduce risk of heart-related disease and death by 25% in another study released last year, said Dr. Donald Lloyd-Jones, chair of preventive medicine at Northwestern University Feinberg School of Medicine.

The new clinical trial, called EVAPORATE, is ongoing and will report final results after 18 months.

Experts hope more data from the trial will show which aspect of the drug's effect on plaque is reducing heart risk.

"We really don't know necessarily yet which of those components of plaque is associated with the most important stabilization and reduction that will translate into reduced clinical events," Lloyd-Jones said.

Vascepa is approved for patients with extremely high levels of triglycerides, a type of fat in the blood associated with heart disease.

The drug's manufacturer, Amarin, is seeking approval from the U.S. Food and Drug Administration for the use of Vascepa in patients who have lower blood fat levels but still have a risk of heart problems, despite taking cholesterol-lowering statins. A month's supply of Vascepa costs roughly $300.

An FDA advisory panel unanimously voted in favor of expanded use of Vascepa last week, basing their decision on research showing that the drug can reduce rates of dangerous heart problems in high-risk patients.

The EVAPORATE trial placed 40 people on high doses of icosapent ethyl and another 40 on a placebo. All participants were already taking statins and had developed at least one artery-clogging plaque. Amarin paid for the trial.

Participants underwent CT scans at the beginning of the study and at nine months to track progression of arterial plaque in their bodies. They'll undergo a final CT scan at 18 months.

Compared to the control group, people on icosapent ethyl experienced a slowdown in plague growth at nine months, including:

  • 42% less progression in total plaque,
  • 89% less new calcified plaque,
  • 57% less new fibrous plaque,
  • 19% less new non-calcified plaque.

Notably, the fish oil drug did not appear to actually melt away plaques, but only slowed down their growth, said Dr. Stephen Nicholls, a professor of cardiology at Monash University in Queensland, Australia.

"There was no evaporation. They all continued to progress," said Nicholls.

There are several possible explanations why icosapent ethyl slows buildup of plaque in the arteries, Nicholls said.

The drug has been shown to reduce triglyceride levels, which contribute to plaque formation. In this study, triglycerides declined, Budoff said.

But the antioxidant and anti-inflammatory effects of the fish oil drug should also be considered as potential contributors, Nicholls said.

Newer trials have tended to support the value of fish oil drugs in controlling arterial plaques, after years of mixed results, Lloyd-Jones and Nicholls said. Both experts were not involved with the new trial.

That's probably because earlier trials did not have people on high enough doses of purified fish oil supplements, Nicholls said.

Other high-dose fish oil clinical trials are ongoing, and will provide further evidence in the near future, Lloyd-Jones said.

More information

The Cleveland Clinic has more about fish oil and heart health.




Facebook

Amazon Smile

 

Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.

 


powered by centersite dot net